Previous 10 | Next 10 |
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Leap Therapeutics Inc. (LPTX) is expected to report $-0.48 for Q3 2023
2023-10-04 09:59:33 ET More on Health Care Select Sector SPDR September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Citi turns cautious on pharmaceuticals and biotech BofA Securities:...
Leap Therapeutics to Participate at Upcoming Investor Conferences PR Newswire CAMBRIDGE, Mass. , Sept. 5, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today an...
2023-08-14 11:17:28 ET Leap Therapeutics press release ( NASDAQ: LPTX ): Q2 GAAP EPS of -$0.91. Cash and cash equivalents totaled $91.4 million at June 30, 2023. Research and development incentive receivables totaled $2.6 million at June 30, 2023. For further details...
Leap Therapeutics Reports Second Quarter 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , Aug, 14, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients PR Newswire CAMBRIDGE, Mass. , July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on dev...
Leap Therapeutics Announces Reverse Stock Split PR Newswire CAMBRIDGE, Mass. , June 20, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it wi...
2023-05-18 15:25:32 ET Why Are Penny Stocks Appealing to Traders? Penny stocks have a unique charm that attracts many traders. These stocks represent shares of small companies trading below $1 per share. Despite their low prices, they offer significant growth potential. This appeal draw...
2023-05-15 10:17:30 ET Leap Therapeutics press release ( NASDAQ: LPTX ): Q1 GAAP EPS of -$0.32 misses by $0.23 . Net Loss was $41.9 million for the first quarter 2023, compared to $10.4 million for the same period in 2022. Cash and cash equivalents totaled $102.0...
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Reports First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today report...
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...